 Clinical trials of Dz13 in patients with basal cell carcinoma commenced in Australia in 2010.In 2013 it was reported that Dz13 was safe and well tolerated after single intratumoral injection at all doses.c-Jun expression was reduced in the excised tumors of all patients injected and tumor depth decreased in the majority.